EdgeMarket › What Bvf Inc/Il reported owning
What Bvf Inc/Il reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
3.1BPositions
41Quarter
2026-03-31Shown below
41largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| KYMR Kymera Therapeutics, Inc. | 458.3M | 14.6% | 5.5M | 119.80 | +182.9% |
| MLTX MoonLake Immunotherapeutics | 298.3M | 9.5% | 16.0M | 15.76 | -70.9% |
| RVMD Revolution Medicines, Inc. | 277.8M | 8.9% | 2.9M | 209.46 | +479.3% |
| NKTR NEKTAR THERAPEUTICS | 184.2M | 5.9% | 2.6M | 74.02 | +174.7% |
| GPCR Structure Therapeutics Inc. | 166.7M | 5.3% | 3.5M | 49.09 | +164.4% |
| MIRM Mirum Pharmaceuticals, Inc. | 146.4M | 4.7% | 1.6M | 96.31 | +44.4% |
| GHRS GH Research PLC | 121.6M | 3.9% | 8.7M | 28.33 | +121.7% |
| PVLA PALVELLA THERAPEUTICS, INC. | 119.8M | 3.8% | 961.0K | 142.04 | +181.6% |
| ZYME Zymeworks Inc. | 93.5M | 3.0% | 3.7M | 28.67 | +100.2% |
| XNCR Xencor Inc | 86.0M | 2.7% | 7.1M | 27.80 | +270.2% |
| STOK Stoke Therapeutics, Inc. | 82.9M | 2.6% | 2.5M | 32.29 | +67.1% |
| CGEM Cullinan Therapeutics, Inc. | 81.7M | 2.6% | 5.8M | 21.68 | +190.2% |
| IRON Disc Medicine, Inc. | 81.4M | 2.6% | 1.3M | 79.81 | +35.9% |
| unmapped CUSIP 98419J206 | 81.3M | 2.6% | 2.6M | — | — |
| OLMA Olema Pharmaceuticals, Inc. | 79.0M | 2.5% | 5.3M | 10.69 | +96.1% |
| TYRA Tyra Biosciences, Inc. | 75.7M | 2.4% | 2.0M | 26.05 | +154.4% |
| GLUE Monte Rosa Therapeutics, Inc. | 73.4M | 2.3% | 4.5M | 14.30 | +222.8% |
| ALKS Alkermes plc. | 70.7M | 2.3% | 2.0M | 48.33 | +66.8% |
| KURA Kura Oncology, Inc. | 68.7M | 2.2% | 8.4M | 11.89 | +68.7% |
| ACIU AC Immune SA | 54.5M | 1.7% | 19.8M | 2.90 | +35.5% |
| CBIO CRESCENT BIOPHARMA, INC. | 50.5M | 1.6% | 2.7M | 17.15 | +24.3% |
| ANNX Annexon, Inc. | 48.2M | 1.5% | 8.7M | 5.07 | +136.9% |
| CMPX Compass Therapeutics, Inc. | 41.1M | 1.3% | 7.8M | 2.40 | -13.7% |
| IMCR Immunocore Holdings plc | 39.0M | 1.2% | 1.3M | 36.88 | +13.5% |
| SEPN Septerna, Inc. | 32.5M | 1.0% | 1.4M | 40.00 | +260.7% |
| STRO SUTRO BIOPHARMA, INC. | 31.2M | 1.0% | 1.3M | 21.04 | +143.4% |
| FHTX Foghorn Therapeutics Inc. | 27.9M | 0.9% | 5.8M | 7.07 | +34.4% |
| FDMT 4D Molecular Therapeutics, Inc. | 26.8M | 0.9% | 2.9M | 15.83 | +131.1% |
| IVVD Invivyd, Inc. | 25.4M | 0.8% | 19.5M | 1.00 | +57.2% |
| AVTX Avalo Therapeutics, Inc. | 24.4M | 0.8% | 1.6M | 19.83 | +115.1% |
| ELDN Eledon Pharmaceuticals, Inc. | 19.4M | 0.6% | 6.3M | 3.45 | +33.7% |
| AVR Anteris Technologies Global Corp. | 16.6M | 0.5% | 3.0M | 8.98 | +152.2% |
| XFOR X4 Pharmaceuticals, Inc | 9.2M | 0.3% | 2.2M | 4.04 | +44.3% |
| IMUX IMMUNIC, INC. | 8.5M | 0.3% | 7.7M | 16.50 | +79.3% |
| OKUR OnKure Therapeutics, Inc. | 8.2M | 0.3% | 2.0M | 3.94 | +44.3% |
| TCRX TScan Therapeutics, Inc. | 5.6M | 0.2% | 5.6M | 0.78 | -54.1% |
| IMA ImageneBio, Inc. | 5.6M | 0.2% | 1.1M | 5.51 | -60.8% |
| TENX TENAX THERAPEUTICS, INC. | 5.4M | 0.2% | 339.5K | 1.75 | -70.7% |
| MOLN MOLECULAR PARTNERS AG | 5.4M | 0.2% | 1.4M | 4.40 | +24.3% |
| IVA Inventiva S.A. | 3.8M | 0.1% | 686.0K | 4.68 | +2.2% |
| ENGNW enGene Therapeutics Inc. | 2.5M | 0.1% | 945.4K | 0.43 | -33.8% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →